<DOC>
	<DOCNO>NCT01684657</DOCNO>
	<brief_summary>The purpose research study find potential benefit safety asenapine ( SaphrisÂ® ) adult suffer developmental form stuttering . It hypothesize individual randomly assign asenapine improvement speech compare placebo .</brief_summary>
	<brief_title>A Randomized , Placebo-Controlled Study Evaluate Efficacy Tolerability Asenapine With Flexible Dosing From 5mg 20mg Adults With Developmental Stuttering</brief_title>
	<detailed_description />
	<mesh_term>Stuttering</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Subjects enrol study meet follow criterion : 1 . Subjects must satisfy DSMIV criterion stutter . 2 . The nature stutter must developmental origin onset prior ten year age . 3 . Subjects must score moderate high SSIIV . 4 ) Women childbearing potential eligible participate long practice medically accept form contraception ( i.e . condom spermicide diaphragm , oral depot contraception , intrauterine device ) . 5 ) Subjects male female age 1870 . 6 ) Subjects English speaking . Subjects exclude study follow reason : 1 . Stuttering related know neurologic cause ( e.g . head trauma , stroke ) . 2 . Unstable medical psychiatric illness . 3 . Active substance abuse within three month prior study inclusion . 4 . Any illness would require concomitant use CNS active medication course study . 5 . Subjects Parkinson 's dementia degenerative neurologic illness . 6 . Subjects pregnant nursing infant . 7 . No minor ( age 18 ) enrol study research compound child adolescent fully perform . 8 . Subjects suffer seizure , irregular heartbeat elevate blood sugar level ( glucose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Stuttering</keyword>
</DOC>